Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ib Abildgaard Jacobsen
The primary object of the study is to estimate the effect of addition of low dose spironolactone to antihypertensive treatment with at least three antihypertensive drugs in patients with type-2 diabetes and blood pressure over 130/80 mmHg.
Secondary aims are to estimate how many of these patients have their blood pressure controlled by the addition of spironolactone, to investigate whether the addition of spironolactone affects insulin sensitivity and urinary protein secretion and to estimate the incidence of adverse effects of the aldosterone antagonist.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \< 75 years
Type-2 diabetes
Therapy resistant hypertension (by ABPM)
Treatment with at least 3 antihypertensives
You may not be if
HbA1c \> 10.0
BP \> 180/110 mmHg
Secondary hypertension
Intolerance to spironolactone
Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids
Total cholesterol 10 mmol/l
New York Heart Association class III and IV
Pregnancy or planned pregnancy
Psychiatric disease
Malignant disease
Insufficient adherence
Clareo Health | The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
